UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

High‐mobility group box‐1 and its role in angiogenesis

Journal of leukocyte biology, 2014-04, Vol.95 (4), p.563-574

2014

Volltextzugriff (PDF)

Abstract CT211: ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab + paclitaxel and cisplatin (TP) versus placebo + TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT211-CT211

2019

Volltextzugriff (PDF)

Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8050-8050

2020

Volltextzugriff (PDF)

Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose

Graefe's archive for clinical and experimental ophthalmology, 2016-05, Vol.254 (5), p.881-890

2016

Volltextzugriff (PDF)

Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7504-7504

2019

Volltextzugriff (PDF)

A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e15125-e15125

2018

Volltextzugriff (PDF)

Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4511-4511

2020

Volltextzugriff (PDF)

2-Methoxyestradiol Alleviates Experimental Autoimmune Uveitis by Inhibiting Lymphocytes Proliferation and T Cell Differentiation

BioMed research international, 2016-01, Vol.2016 (2016), p.1-8

2016

Volltextzugriff (PDF)

Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-[beta] and high glucose

Graefe's archive for clinical and experimental ophthalmology, 2016-05, Vol.254 (5), p.881

2016

Volltextzugriff (PDF)

Epo inhibits the fibrosis and migration of Mueller glial cells induced by TGF- beta and high glucose

Graefe's archive for clinical and experimental ophthalmology, 2016-05, Vol.254 (5), p.881-890

2016

Volltextzugriff (PDF)

Abstract CT176: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT176-CT176

2023

Volltextzugriff (PDF)

Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT110-CT110

2023

Volltextzugriff (PDF)

Subretinal injection of amyloid-β peptide accelerates RPE cell senescence and retinal degeneration

International journal of molecular medicine, 2015-01, Vol.35 (1), p.169-176

2015

Volltextzugriff (PDF)

Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)

SSRN Electronic Journal

Volltextzugriff (PDF)

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)

Sprache

Englisch
(14)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

High‐mobility group box‐1 and its role in angiogenesis

Abstract CT211: ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab + paclitaxel and cisplatin (TP) versus placebo + TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma

Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4)

Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-β and high glucose

Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4)

A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors

Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2)

2-Methoxyestradiol Alleviates Experimental Autoimmune Uveitis by Inhibiting Lymphocytes Proliferation and T Cell Differentiation

Epo inhibits the fibrosis and migration of Müller glial cells induced by TGF-[beta] and high glucose

Epo inhibits the fibrosis and migration of Mueller glial cells induced by TGF- beta and high glucose

Abstract CT176: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors

Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors

Subretinal injection of amyloid-β peptide accelerates RPE cell senescence and retinal degeneration

Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)

Suchergebnisse filtern